Vivoryon Therapeutics to Release H1 2026 Financial Results and Update on Kidney Disease Pipeline on August 6

Schedule and Format for Vivoryon's August 6 Financial Disclosure

Vivoryon Therapeutics will release its half-year financial results and operational updates on Thursday, August 6, 2026, covering the six-month period ending June 30, 2026. This disclosure provides investors and stakeholders with insights into the company’s financial performance and clinical development progress during the first half of the year. The announcement aligns with standard biotech sector practices of interim reporting to highlight key milestones and financial status.

The H1 2026 report will be available for download on Vivoryon’s financial information webpage. Additionally, a public conference call and webcast will accompany the release, facilitating direct interaction between management and the investment community. This combined approach ensures transparent communication and allows analysts, shareholders, and institutional investors to engage with company leadership and clarify business outlooks.

Details for the H1 2026 Conference Call and Webcast

The conference call for H1 2026 results is scheduled for 3:00 pm Central European Summer Time (CEST) / 9:00 am Eastern Daylight Time (EDT) on August 6, 2026. Participants can join via a live audio webcast on Vivoryon’s website or by telephone dial-in. Interested parties are encouraged to pre-register through a dedicated portal to receive dial-in numbers and access credentials, ensuring seamless connectivity. It is recommended to log in or call approximately 15 minutes before the start time to avoid technical issues.

The webcast will be hosted on Vivoryon’s news and events presentations page, enabling global access to management’s remarks and the Q&A session. This dual access format maximizes participation regardless of location or technical preference and provides a permanent record accessible after the live event, promoting transparency for all stakeholders.

Vivoryon’s Clinical Pipeline and Therapeutic Focus

Vivoryon Therapeutics is a clinical-stage biotech company dedicated to developing innovative small molecule treatments for inflammatory and fibrotic kidney disorders. The company’s focused pipeline targets kidney diseases, concentrating research, clinical development, and regulatory efforts on this specialized area. This strategic focus addresses significant unmet medical needs, especially in chronic kidney disease linked to metabolic conditions.

The company’s drug discovery approach modulates activity and stability of disease-relevant proteins to alter progression of severe kidney diseases. By leveraging "ground-breaking science and innovation," Vivoryon aims to develop precision medicines that go beyond symptom management to improve long-term patient outcomes and quality of life.

Varoglutamstat: Lead Candidate for Diabetic Kidney Disease

Varoglutamstat is Vivoryon’s most advanced programme, a proprietary, first-in-class oral QPCT/L inhibitor under clinical evaluation for diabetic kidney disease. This condition, characterized by progressive kidney dysfunction in diabetic patients, is a leading cause of end-stage renal disease worldwide, representing a major therapeutic opportunity.

As a first-in-class agent, varoglutamstat targets a novel pathway distinct from existing treatments, potentially offering significant clinical and regulatory advantages. Its oral formulation may enhance patient convenience and adherence compared to injectable therapies. Management commentary during the August 6 call is expected to focus on clinical trial progress, safety and efficacy data, and regulatory outlook for this key asset.

Market Listing and Operational Presence

Vivoryon Therapeutics N.V. is listed on Euronext Amsterdam under ticker VVY with reference code NL00150002Q7. The company operates from Halle (Saale) and Munich, Germany, positioning itself within a prominent European biotech hub. This dual German presence supports clinical development and regulatory engagement within the European healthcare ecosystem.

Listing on Euronext Amsterdam provides access to European institutional investors and facilitates capital market activities. Vivoryon’s website (www.vivoryon.com) serves as the central platform for investor relations, financial disclosures, and corporate news, ensuring transparency and compliance with regulatory requirements.

Annual General Meeting Scheduled for September 2026

Vivoryon has scheduled its 2026 Annual General Meeting for late September, with convocation materials to be published on the company website ahead of the meeting. The AGM is a key governance event where shareholders vote on board appointments, executive compensation, dividends, and other corporate matters.

The timing allows shareholders to review the H1 2026 financial results prior to the meeting. Specific details on the exact date and venue will be communicated via the formal convocation notice, consistent with standard corporate governance practices.

Corporate Structure and Investor Relations

Registered as a Dutch Naamloze Vennootschap (N.V.), Vivoryon complies with European capital market regulations and Euronext listing standards. The company has a dedicated investor relations team led by Dr. Manuela Bader, Director of Investor Relations and Communications, ensuring professional and transparent engagement with investors.

External investor relations support is provided by LifeSci Advisors, with Sandya von der Weid serving as an external contact. This combined internal and external IR approach aligns with best practices for clinical-stage biotech firms managing investor communications efficiently.

Small Molecule Development Strategy in Kidney Disease

Vivoryon’s focus on small molecule drugs for kidney inflammation and fibrosis offers advantages such as oral bioavailability, intracellular target engagement, and potentially lower manufacturing costs compared to biologics. The kidney disease market has been dominated by large molecules and symptomatic therapies, creating opportunities for innovative small molecule agents targeting novel pathways.

The company’s strategy to modulate disease-relevant protein activity aims to address underlying disease mechanisms rather than symptoms alone, with the objective to alter disease progression. This ambitious approach carries higher development risk but promises significant therapeutic advances if successful.

Forward-Looking Statements and Regulatory Outlook

The announcement includes standard cautionary statements regarding risks and uncertainties inherent in clinical-stage biotechnology development. Vivoryon notes that operational results, financial condition, and strategic outcomes may differ materially from projections. The clinical advancement of varoglutamstat depends on successful trial results, regulatory approvals, and competitive positioning.

Investors are advised to review detailed risk disclosures in the company’s published financial statements. The August 6 results release and September AGM will provide forums for assessing management’s confidence in clinical progress and capital resources to support ongoing development.

Investor Access to Information and Disclosure Compliance

Vivoryon maintains a dedicated financial information section on its website (https://www.vivoryon.com/financial-information/) where the H1 2026 report will be published and available for download. This centralized repository ensures easy access to interim and historical financial disclosures, supporting transparency and regulatory compliance.

The simultaneous publication of the report and live conference call exemplifies adherence to international best practices in financial communication, promoting equal information access and market fairness. Investors are encouraged to monitor the company website for ongoing updates related to clinical development, regulatory filings, and corporate announcements.